
|Articles|July 1, 2001
Molecular assays may aid bladder cancer control
Washington-An evolution in the management of bladder cancer, including the use of molecular-based diagnostic testing, may soon make it possible to achieve better outcomes at a lower cost, according to Mark P. Schoenberg, MD. Dr. Schoenberg, associate professor of urology and oncology and director of the bladder cancer research center at the Johns Hopkins School of Medicine in Baltimore, said that a change in some aspects of bladder cancer management is sorely needed.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Mark Tyson, MD shares promising BOND-003 results in papillary NMIBC
2
Gemcitabine intravesical system delivers high 12-month DFS in papillary-only NMIBC
3
CORE-008: Cretostimogene achieves high CR rate in high-risk NMIBC
4
Modern frameworks for treating high-risk non–muscle invasive bladder cancer
5


















